Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Injectable nanogels to improve triamcinolone acetonide delivery and toxicity on the treatment of eye diseases.
J Biomater Appl
January 2025
Faculty of Medicine, Advanced Technologies Application and Research Center, Ankara Yıldırım Beyazıt University, Ankara, Turkey.
Triamcinolone acetonide (TA) is a corticosteroid, and widely used in the treatment of eye diseases such as macular edema, proliferative vitreoretinopathy, and chronic uveitis. It's also used in diseases such as osteoarthritis and rheumatoid arthritis. Despite the width of its usage, it has toxicity in the eye.
View Article and Find Full Text PDFResolution of Plaque Keratopathy in a Patient with Atopic Keratoconjunctivitis After Treatment with Leflunomide.
Ocul Immunol Inflamm
December 2024
Department of Ophthalmology, University of Illinois Eye and Ear Infirmary, Chicago, Illinois, USA.
Purpose: To report a case of resolution of corneal findings in a patient with atopic keratoconjunctivitis after treatment with leflunomide.
Methods: Case report.
Results: A 57-year-old male presented with ocular signs and symptoms consistent with severe atopic keratoconjunctivitis.
Rapid identification of inflammatory arthritis and associated adverse events following immune checkpoint therapy: a machine learning approach.
Front Immunol
April 2024
Center for Health Information Partnerships, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.
Introduction: Immune checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) poses a major clinical challenge to ICI therapy for cancer, with 13% of cases halting ICI therapy and ICI-IA being difficult to identify for timely referral to a rheumatologist. The objective of this study was to rapidly identify ICI-IA patients in clinical data and assess associated immune-related adverse events (irAEs) and risk factors.
Methods: We conducted a retrospective study of the electronic health records (EHRs) of 89 patients who developed ICI-IA out of 2451 cancer patients who received ICI therapy at Northwestern University between March 2011 to January 2021.
Inflammation-Targeting Mesenchymal Stem Cells Combined with Photothermal Treatment Attenuate Severe Joint Inflammation.
Adv Mater
March 2024
Department of Health Sciences and Technology, GAIHST, Gachon University, Incheon, 21999, South Korea.
Current clinical therapeutic efficacy for the treatment of osteo- and rheumatoid-arthritis is obviously limited. Although mesenchymal stem cells (MSCs) are considered as a source of promising regenerative therapy, un-modified or genetically engineered MSCs injected in vivo restrict their clinical utility because of the low drug efficacy and unpredicted side effect, respectively. Herein, a strategy to enhance the migration efficacy of MSCs to inflamed joints via an inflammation-mediated education process is demonstrated.
View Article and Find Full Text PDFSuprachoroidal Triamcinolone Injection in Posterior Scleritis: A Case Report.
Ocul Immunol Inflamm
September 2024
Massachusetts Eye Research and Surgery Institution, Waltham, Massachusetts, USA.
Suprachoroidal triamcinolone acetonide (SCS-TA) injections were recently approved to treat macular edema secondary to noninfectious uveitis. However, its use in managing posterior scleritis has not been reported. We report the first case of SCS-TA used in the treatment of posterior scleritis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!